



**Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2015
Table of Contents**

Table 1: GAAP P&L.....	1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.....	2
Table 2a: GAAP to Non-GAAP P&L Reconciliation 2Q15	3
Table 2b: GAAP to Non-GAAP P&L Reconciliation June YTD 15	4
Table 2c: GAAP to Non-GAAP P&L Reconciliation 2Q14.....	5
Table 2d: GAAP to Non-GAAP P&L Reconciliation June YTD 14	6
Table 3: Sales – Current Year and Prior Year by Quarter	7
Table 3a: Sales – U.S. / Ex- U.S. 2Q15	8
Table 3b: Sales – U.S. / Ex- U.S. June YTD 15.....	9
Table 3c: Sales – Pharmaceutical Geographic Split	10
Table 4: Other (Income) Expense	11

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1

	GAAP		% Change	GAAP		% Change
	2Q15	2Q14		June YTD 2015	June YTD 2014	
Sales	\$ 9,785	\$ 10,934	-11%	\$ 19,210	\$ 21,198	-9%
Costs, Expenses and Other						
Materials and production ⁽¹⁾	3,754	4,893	-23%	7,323	8,796	-17%
Marketing and administrative ⁽¹⁾	2,624	2,973	-12%	5,226	5,707	-8%
Research and development ⁽¹⁾	1,670	1,664	--	3,407	3,238	5%
Restructuring costs ⁽²⁾	191	163	17%	273	288	-5%
Other (income) expense, net ⁽¹⁾⁽³⁾	739	(650)	*	793	(813)	*
Income Before Taxes	807	1,891	-57%	2,188	3,982	-45%
Income Tax Provision	119	(142)		542	218	
Net Income	688	2,033	-66%	1,646	3,764	-56%
Less: Net Income Attributable to Noncontrolling Interests	1	29		7	55	
Net Income Attributable to Merck & Co., Inc.	\$ 687	\$ 2,004	-66%	\$ 1,639	\$ 3,709	-56%
Earnings per Common Share Assuming Dilution	\$ 0.24	\$ 0.68	-65%	\$ 0.57	\$ 1.25	-54%
Average Shares Outstanding Assuming Dilution	2,850	2,949		2,856	2,957	
Tax Rate ⁽⁴⁾	14.7%	-7.5%		24.8%	5.5%	

* 100% or greater

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.

(3) Other (income) expense, net in the second quarter and first six months of 2015 includes foreign exchange losses of \$715 million to revalue the company's net monetary assets in Venezuela. Other (income) expense, net in the second quarter and first six months of 2014 includes a gain of \$741 million related to AstraZeneca's option exercise. In addition, other (income) expense, net in the first six months of 2014 includes gains of \$204 million related to the divestiture of the company's Sirna Therapeutics, Inc. subsidiary. Other (income) expense, net includes equity income from affiliates. Prior period amounts have been reclassified to conform to the current presentation.

(4) The effective income tax rates for the second quarter and first six months of 2015 reflect a net benefit of \$370 million related to the settlement of certain federal income tax issues, partially offset by the unfavorable impact of foreign exchange losses recorded in connection with the revaluation of the company's net monetary assets in Venezuela for which no tax benefit was recorded. The effective income tax rates for the second quarter and first six months of 2014 reflect a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise. In addition, the effective income tax rate for the first six months of 2014 reflects a benefit of approximately \$300 million associated with a capital loss generated in the first quarter of 2014.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 1a

	2015			2014						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Dec YTD	2Q	June YTD
Sales	\$ 9,425	\$ 9,785	\$ 19,210	\$ 10,264	\$ 10,934	\$ 21,198	\$ 10,557	\$ 10,482	\$ 42,237	-11%	-9%
Costs, Expenses and Other											
Materials and production	3,569	3,754	7,323	3,903	4,893	8,796	4,223	3,749	16,768	-23%	-17%
Marketing and administrative	2,601	2,624	5,226	2,734	2,973	5,707	2,975	2,924	11,606	-12%	-8%
Research and development	1,737	1,670	3,407	1,574	1,664	3,238	1,659	2,283	7,180	--	5%
Restructuring costs	82	191	273	125	163	288	376	349	1,013	17%	-5%
Other (income) expense, net ⁽¹⁾	55	739	793	(163)	(650)	(813)	(166)	(10,634)	(11,613)	*	*
Income Before Taxes	1,381	807	2,188	2,091	1,891	3,982	1,490	11,811	17,283	-57%	-45%
Income Tax Provision (Benefit)	423	119	542	360	(142)	218	648	4,484	5,349		
Net Income	958	688	1,646	1,731	2,033	3,764	842	7,327	11,934	-66%	-56%
Less: Net Income (Loss) Attributable to Noncontrolling Interests	5	1	7	26	29	55	(53)	11	14		
Net Income Attributable to Merck & Co., Inc.	\$ 953	\$ 687	\$ 1,639	\$ 1,705	\$ 2,004	\$ 3,709	\$ 895	\$ 7,316	\$ 11,920	-66%	-56%
Earnings per Common Share Assuming Dilution	\$ 0.33	\$ 0.24	\$ 0.57	\$ 0.57	\$ 0.68	\$ 1.25	\$ 0.31	\$ 2.54	\$ 4.07	-65%	-54%
Average Shares Outstanding Assuming Dilution	2,865	2,850	2,856	2,971	2,949	2,957	2,911	2,880	2,928		
Tax Rate	30.6%	14.7%	24.8%	17.2%	-7.5%	5.5%	43.5%	38.0%	30.9%		

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Other (income) expense, net includes equity income from affiliates. Prior periods have been reclassified to conform to the current presentation.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2015
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2a

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 9,785					\$ 9,785
Costs, Expenses and Other						
Materials and production	3,754	1,241	105		1,346	2,408
Marketing and administrative	2,624	136	17		153	2,471
Research and development	1,670	71	15		86	1,584
Restructuring costs	191		191		191	-
Other (income) expense, net ⁽⁴⁾	739			715	715	24
Income Before Taxes	807	(1,448)	(328)	(715)	(2,491)	3,298
Taxes on Income	119				(737) ⁽⁵⁾	856
Net Income	688				(1,754)	2,442
Less: Net Income Attributable to Noncontrolling Interests	1					1
Net Income Attributable to Merck & Co., Inc.	\$ 687				(1,754)	\$ 2,441
Earnings per Common Share Assuming Dilution	\$ 0.24					\$ 0.86
Average Shares Outstanding Assuming Dilution	2,850					2,850
Tax Rate	14.7%					26.0%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect \$1.2 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as \$44 million of amortization of purchase accounting adjustments to inventories as a result of the Cubist acquisition. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company's formal restructuring programs, as well as transaction and certain other costs related to divestitures. Amounts included in research and development expenses reflect \$59 million of in-process research and development ("IPR&D") impairment charges, as well as \$12 million of charges to increase the fair value of liabilities for contingent consideration.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents foreign exchange losses of \$715 million to revalue the company's net monetary assets in Venezuela.

(4) Other (income) expense, net includes equity income from affiliates.

(5) Represents the estimated tax impact on the reconciling items, as well as a net benefit of \$370 million on the settlement of certain federal income tax issues.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2015
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2b

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 19,210					\$ 19,210
Costs, Expenses and Other						
Materials and production	7,323	2,491	210		2,701	4,622
Marketing and administrative	5,226	363	53		416	4,810
Research and development	3,407	134	17		151	3,256
Restructuring costs	273		273		273	-
Other (income) expense, net ⁽⁴⁾	793			701	701	92
Income Before Taxes	2,188	(2,988)	(553)	(701)	(4,242)	6,430
Taxes on Income	542				(1,015) ⁽⁵⁾	1,557
Net Income	1,646				(3,227)	4,873
Less: Net Income Attributable to Noncontrolling Interests	7					7
Net Income Attributable to Merck & Co., Inc.	\$ 1,639				(3,227)	\$ 4,866
Earnings per Common Share Assuming Dilution	\$ 0.57					\$ 1.70
Average Shares Outstanding Assuming Dilution	2,856					2,856
Tax Rate	24.8%					24.2%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect \$2.4 billion of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as \$65 million of amortization of purchase accounting adjustments to inventories as a result of the Cubist acquisition. Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company's formal restructuring programs, as well as transaction and certain other costs related to divestitures. Amounts included in research and development expenses reflect \$73 million of charges to increase the fair value of liabilities for contingent consideration, as well as \$61 million of in-process research and development ("IPR&D") impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Includes foreign exchange losses of \$715 million to revalue the company's net monetary assets in Venezuela.

(4) Other (income) expense, net includes equity income from affiliates.

(5) Represents the estimated tax impact on the reconciling items, as well as a net benefit of \$370 million on the settlement of certain federal income tax issues.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SECOND QUARTER 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2c

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 10,934					\$ 10,934
Costs, Expenses and Other						
Materials and production	4,893	1,724	171		1,895	2,998
Marketing and administrative	2,973	32	44		76	2,897
Research and development	1,664		43		43	1,621
Restructuring costs	163		163		163	-
Other (income) expense, net	(650)			(741)	(741)	91
Income Before Taxes	1,891	(1,756)	(421)	741	(1,436)	3,327
Taxes on Income	(142)				(947) ⁽⁴⁾	805
Net Income	2,033				(489)	2,522
Less: Net Income Attributable to Noncontrolling Interests	29					29
Net Income Attributable to Merck & Co., Inc.	\$ 2,004				(489)	\$ 2,493
Earnings per Common Share Assuming Dilution	\$ 0.68					\$ 0.85
Average Shares Outstanding Assuming Dilution	2,949					2,949
Tax Rate	-7.5%					24.2%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$1.1 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$660 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents a gain related to AstraZeneca's option exercise.

(4) Represents the estimated tax impact on the reconciling items, including a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise.

MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME
GAAP TO NON-GAAP RECONCILIATION
SIX MONTHS ENDED JUNE 30, 2014
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

Table 2d

	GAAP	Acquisition and Divestiture- Related Costs ⁽¹⁾	Restructuring Costs ⁽²⁾	Certain Other Items ⁽³⁾	Adjustment Subtotal	Non-GAAP
Sales	\$ 21,198					\$ 21,198
Costs, Expenses and Other						
Materials and production	8,796	2,850	290		3,140	5,656
Marketing and administrative	5,707	43	75		118	5,589
Research and development	3,238		94		94	3,144
Restructuring costs	288		288		288	-
Other (income) expense, net	(813)			(741)	(741)	(72)
Income Before Taxes	3,982	(2,893)	(747)	741	(2,899)	6,881
Taxes on Income	218				(1,514) ⁽⁴⁾	1,732
Net Income	3,764				(1,385)	5,149
Less: Net Income Attributable to Noncontrolling Interests	55					55
Net Income Attributable to Merck & Co., Inc.	\$ 3,709				(1,385)	\$ 5,094
Earnings per Common Share Assuming Dilution	\$ 1.25					\$ 1.72
Average Shares Outstanding Assuming Dilution	2,957					2,957
Tax Rate	5.5%					25.2%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs reflect expenses of \$2.2 billion for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as \$660 million of impairment charges on product intangibles. Amounts included in marketing and administrative expenses reflect merger integration costs, as well as transaction and certain other costs related to business acquisitions and divestitures.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company's formal restructuring programs.

(3) Represents a gain related to AstraZeneca's option exercise.

(4) Represents the estimated tax impact on the reconciling items, including a net benefit of \$517 million recorded in connection with AstraZeneca's option exercise, as well as a benefit of approximately \$300 million associated with a capital loss generated in the first quarter.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)

Table 3

	2015			2014						% Change	
	1Q	2Q	June YTD	1Q	2Q	June YTD	3Q	4Q	Full Year	2Q	June YTD
TOTAL SALES ⁽¹⁾	\$ 9,425	\$ 9,785	\$ 19,210	\$ 10,264	\$ 10,934	\$ 21,198	\$ 10,557	\$ 10,482	\$ 42,237	-11	-9
PHARMACEUTICAL	8,266	8,564	16,830	8,451	9,087	17,538	9,134	9,370	36,042	-6	-4
Primary Care & Women's Health											
Cardiovascular											
Zetia	568	635	1,202	611	717	1,328	660	662	2,650	-11	-9
Vytorin	320	320	640	361	417	777	369	370	1,516	-23	-18
Diabetes											
Januvia	884	1,044	1,928	858	1,058	1,916	933	1,082	3,931	-1	1
Janumet	509	554	1,063	476	519	995	505	570	2,071	7	7
General Medicine & Women's Health											
NuvaRing	166	182	348	168	178	346	186	191	723	2	1
Implanon / Nexplanon	137	124	261	102	119	221	158	123	502	4	18
Dulera	130	120	251	102	103	205	124	132	460	17	22
Follistim AQ	82	111	193	110	102	213	97	102	412	9	-9
Hospital and Specialty											
Hepatitis											
PegIntron	56	52	108	112	103	216	84	81	381	-50	-50
HIV											
Isentress	385	375	760	390	453	843	412	418	1,673	-17	-10
Hospital Acute Care											
Cubicin ⁽²⁾	187	293	480	5	6	11	7	7	25	*	*
Cancidas	163	134	297	166	156	322	183	175	681	-14	-8
Invanz	132	139	271	114	134	249	141	139	529	4	9
Noxafil	111	117	228	74	98	172	107	122	402	19	32
Bridion	85	87	172	73	82	155	90	95	340	6	11
Primaxin	65	88	153	71	81	151	91	86	329	9	1
Immunology											
Remicade	501	455	956	604	607	1,211	604	557	2,372	-25	-21
Simponi	158	169	327	157	174	330	170	188	689	-3	-1
Oncology											
Emend	122	134	255	122	144	266	136	151	553	-7	-4
Keytruda	83	110	192	0	0	0	4	50	55	*	*
Temodar	74	80	155	83	93	176	88	86	350	-14	-12
Diversified Brands											
Respiratory											
Nasonex	289	215	504	312	258	570	261	268	1,099	-16	-11
Singulair	245	212	457	271	284	554	218	319	1,092	-25	-18
Clarinx	51	55	106	62	69	131	49	52	232	-20	-19
Other											
Cozaar / Hyzaar	185	189	374	205	214	419	195	192	806	-12	-11
Arcoxia	123	115	238	128	141	268	132	118	519	-18	-11
Fosamax	94	96	190	123	121	245	114	112	470	-21	-22
Zocor	49	63	112	64	69	133	61	64	258	-9	-16
Propecia	53	39	92	74	58	131	66	67	264	-32	-30
Vaccines											
Gardasil / Gardasil 9	359	427	785	383	409	792	590	356	1,738	4	-1
ProQuad, M-M-R II and Varivax	348	358	705	280	326	606	421	366	1,394	10	16
Zostavax	175	149	324	142	156	298	181	285	765	-4	9
RotaTeq	192	89	281	169	147	316	174	169	659	-40	-11
Pneumovax 23	110	106	216	101	102	203	197	346	746	4	7
Other Pharmaceutical ⁽³⁾	1,075	1,128	2,206	1,378	1,389	2,769	1,326	1,269	5,356	-19	-20
ANIMAL HEALTH	829	840	1,669	813	872	1,685	885	885	3,454	-4	-1
CONSUMER CARE ⁽⁴⁾	2	0	2	546	583	1,130	401	16	1,547	*	*
Other Revenues ⁽⁵⁾	328	381	709	454	392	845	137	211	1,194	-3	-16

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Cubicin results for the first quarter 2015 represent sales for the two months following Merck's acquisition of Cubist. Cubicin sales for 2014 represent the previous licensing agreement in Japan prior to the acquisition.

⁽³⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$78 million and \$76 million for the first and second quarters of 2015. Other Vaccines sales included in Other Pharmaceutical were \$98 million, \$76 million, \$116 million and \$88 million for the first, second, third and fourth quarters of 2014, respectively.

⁽⁴⁾ On October 1, 2014, the company divested the Consumer Care business to Bayer.

⁽⁵⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products. Other revenues in the first quarter 2014 include \$232 million of revenue recognized in connection with the sale of U.S. *Saphris* rights.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2015
(AMOUNTS IN MILLIONS)

Table 3a

	Global			U.S.			International		
	2Q 2015	2Q 2014	% Change	2Q 2015	2Q 2014	% Change	2Q 2015	2Q 2014	% Change
TOTAL SALES ⁽¹⁾	\$9,785	\$10,934	-11	\$4,265	\$4,429	-4	\$5,520	\$6,505	-15
PHARMACEUTICAL	8,564	9,087	-6	3,934	3,462	14	4,631	5,625	-18
Primary Care and Women's Health									
Cardiovascular									
Zetia	635	717	-11	409	408		226	309	-27
Vytorin	320	417	-23	123	158	-22	197	259	-24
Diabetes									
Januvia	1,044	1,058	-1	648	566	14	396	492	-20
Janumet	554	519	7	263	235	12	292	284	3
General Medicine & Women's Health									
NuvaRing	182	178	2	126	112	13	56	66	-16
Implanon / Nexplanon	124	119	4	74	67	10	50	52	-3
Dulera	120	103	17	116	98	18	5	5	-10
Follistim AQ	111	102	9	52	30	71	60	72	-17
Hospital and Specialty									
Hepatitis									
PegIntron	52	103	-50		8	*	52	95	-46
HIV									
Isentress	375	453	-17	212	228	-7	163	225	-27
Hospital Acute Care									
Cubicin ⁽²⁾	293	6	*	266			27	6	*
Candidas	134	156	-14	7	4	57	127	152	-16
Invanz	139	134	4	79	64	24	60	71	-15
Noxafil	117	98	19	50	35	43	67	63	6
Bridion	87	82	6				87	82	6
Primaxin	88	81	9	1		*	87	81	7
Immunology									
Remicade	455	607	-25				455	607	-25
Simponi	169	174	-3				169	174	-3
Oncology									
Emend	134	144	-7	79	78	1	55	66	-17
Keytruda	110		*	86		*	24		*
Temodar	80	93	-14	2	5	-57	78	88	-11
Diversified Brands									
Respiratory									
Nasonex	215	258	-16	124	141	-12	91	117	-22
Singular	212	284	-25	10	8	19	201	275	-27
Clarinet	55	69	-20	6	5	27	49	64	-24
Other									
Cozaar / Hyzaar	189	214	-12	9	8	6	180	206	-12
Arcoxia	115	141	-18				115	141	-18
Fosamax	96	121	-21	3	6	-44	93	116	-20
Zocor	63	69	-9	5	5	-7	58	63	-9
Propecia	39	58	-32	4	5	-23	35	53	-33
Vaccines									
Gardasil / Gardasil 9	427	409	4	308	294	5	118	115	3
ProQuad, M-M-R II and Varivax	358	326	10	301	276	9	57	50	13
Zostavax	149	156	-4	107	116	-8	43	40	5
RotaTeq	89	147	-40	48	101	-53	41	46	-11
Pneumovax 23	106	102	4	70	85	-17	35	17	*
Other Pharmaceutical ⁽³⁾	1,128	1,389	-19	346	316	9	782	1,073	-27
ANIMAL HEALTH	840	872	-4	215	185	16	625	687	-9
CONSUMER CARE ⁽⁴⁾	0	583	*	0	406	*	0	177	*
Other Revenues ⁽⁵⁾	381	392	-3	117	376	-69	264	16	*

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Cubicin sales for 2014 represent the previous licensing agreement in Japan prior to the acquisition.

⁽³⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$76 million on a global basis for both second quarter 2015 and 2014.

⁽⁴⁾ On October 1, 2014, the company divested the Consumer Care business to Bayer.

⁽⁵⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products.

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2015
(AMOUNTS IN MILLIONS)

Table 3b

	Global			U.S.			International		
	June YTD 15	June YTD 14	% Change	June YTD 15	June YTD 14	% Change	June YTD 15	June YTD 14	% Change
TOTAL SALES ⁽¹⁾	\$19,210	\$21,198	-9	\$8,218	\$8,574	-4	\$10,992	\$12,624	-13
PHARMACEUTICAL	16,830	17,538	-4	7,571	6,592	15	9,259	10,946	-15
Primary Care and Women's Health									
Cardiovascular									
Zetia	1,202	1,328	-9	754	732	3	448	596	-25
Vytorin	640	777	-18	234	277	-16	406	500	-19
Diabetes									
Januvia	1,928	1,916	1	1,149	1,040	10	779	876	-11
Janumet	1,063	995	7	475	448	6	589	547	8
General Medicine & Women's Health									
NuvaRing	348	346	1	238	215	11	110	131	-16
Implanon / Nexplanon	261	221	18	158	127	25	103	94	10
Dulera	251	205	22	241	194	24	10	10	-1
Follistim AQ	193	213	-9	86	64	33	107	148	-28
Hospital and Specialty									
Hepatitis									
PegIntron	108	216	-50		12	*	108	203	-47
HIV									
Isentress	760	843	-10	399	419	-5	362	424	-15
Hospital Acute Care									
Cubicin ⁽²⁾	480	11	*	432			48	11	*
Candidas	297	322	-8	13	11	16	284	311	-9
Invanz	271	249	9	146	123	18	125	125	
Noxafil	228	172	32	95	55	74	133	118	13
Bridion	172	155	11				172	155	11
Primaxin	153	151	1	4	3	33	149	148	
Immunology									
Remicade	956	1,211	-21				956	1,211	-21
Simponi	327	330	-1				327	330	-1
Oncology									
Emend	255	266	-4	157	148	6	98	118	-17
Keytruda	192		*	152		*	40		*
Temodar	155	176	-12		4	*	155	172	-10
Diversified Brands									
Respiratory									
Nasonex	504	570	-11	267	274	-3	237	295	-20
Singular	457	554	-18	16	13	20	441	541	-19
Clarinx	106	131	-19	12	11	1	95	120	-21
Other									
Cozaar / Hyzaar	374	419	-11	17	14	17	357	405	-12
Arcoxia	238	268	-11				238	268	-11
Fosamax	190	245	-22	6	9	-36	184	235	-22
Zocor	112	133	-16	10	10	-1	102	123	-17
Propecia	92	131	-30	8	10	-20	85	122	-30
Vaccines									
Gardasil / Gardasil 9	785	792	-1	603	564	7	182	228	-20
ProQuad, M-M-R II and Varivax	705	606	16	609	517	18	96	89	8
Zostavax	324	298	9	257	245	5	67	53	25
RotaTeq	281	316	-11	205	231	-11	76	85	-10
Pneumovax 23	216	203	7	147	168	-12	69	35	97
Other Pharmaceutical ⁽³⁾	2,206	2,769	-20	681	654	4	1,524	2,119	-28
ANIMAL HEALTH	1,669	1,685	-1	417	362	15	1,251	1,323	-5
CONSUMER CARE ⁽⁴⁾	2	1,130	*	0	796	*	2	334	-99
Other Revenues ⁽⁵⁾	709	845	-16	230	825	-72	479	20	*

* 100% or greater

⁽¹⁾ Only select products are shown.

⁽²⁾ Cubicin results for the June YTD 2015 period represent sales for the five months following Merck's acquisition of Cubist. Cubicin sales for 2014 represent the previous licensing agreement in Japan prior to the acquisition.

⁽³⁾ Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were \$156 million and \$175 million on a global basis for June YTD 2015 and 2014, respectively.

⁽⁴⁾ On October 1, 2014, the company divested the Consumer Care business to Bayer.

⁽⁵⁾ Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other revenues in 2014 include \$232 million of revenue recognized in connection with the sale of U.S. *Saphris* rights. On June 30, 2014, AstraZeneca exercised its option to buy Merck's interest in a subsidiary and through it, Merck's interest in Nexium and Prilosec. As a result, the company no longer records supply sales for these products.

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)

Table 3c

	2015			2014						% Change 2Q	% Change June YTD
	1Q 2015	2Q 2015	June YTD	1Q 2014	2Q 2014	June YTD	3Q 2014	4Q 2014	Full Year		
TOTAL PHARMACEUTICAL	\$8,266	\$8,564	\$16,830	\$8,451	\$9,087	\$17,538	\$9,134	\$9,370	\$36,042	-6	-4
United States	3,637	3,934	7,571	3,130	3,462	6,592	3,837	3,786	14,214	14	15
% Pharmaceutical Sales	44.0%	45.9%	45.0%	37.0%	38.1%	37.6%	42.0%	40.4%	39.4%		
Europe ⁽¹⁾	2,024	1,896	3,920	2,478	2,537	5,015	2,297	2,269	9,581	-25	-22
% Pharmaceutical Sales	24.5%	22.1%	23.3%	29.3%	27.9%	28.6%	25.2%	24.2%	26.6%		
Japan	627	629	1,256	835	859	1,694	730	965	3,389	-27	-26
% Pharmaceutical Sales	7.6%	7.3%	7.5%	9.9%	9.5%	9.7%	8.0%	10.3%	9.4%		
Asia Pacific	809	822	1,630	809	840	1,650	878	910	3,438	-2	-1
% Pharmaceutical Sales	9.8%	9.6%	9.7%	9.6%	9.2%	9.4%	9.6%	9.7%	9.5%		
China	318	335	653	282	309	592	318	332	1,242	8	10
Latin America	630	676	1,306	538	668	1,205	673	678	2,557	1	8
% Pharmaceutical Sales	7.6%	7.9%	7.8%	6.4%	7.3%	6.9%	7.4%	7.2%	7.1%		
Eastern Europe/Middle East Africa	321	372	693	415	459	874	443	500	1,817	-19	-21
% Pharmaceutical Sales	3.9%	4.3%	4.1%	4.9%	5.1%	5.0%	4.9%	5.3%	5.0%		
Canada	170	167	337	200	218	418	218	218	854	-23	-19
% Pharmaceutical Sales	2.1%	2.0%	2.0%	2.4%	2.4%	2.4%	2.4%	2.3%	2.4%		
Other	48	68	117	46	44	90	58	44	192	55	30
% Pharmaceutical Sales	0.6%	0.8%	0.7%	0.5%	0.5%	0.5%	0.6%	0.5%	0.5%		

(1) Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.
SECOND QUARTER 2015
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4

OTHER (INCOME) EXPENSE, NET

	2Q15	2Q14	June YTD 2015	June YTD 2014
INTEREST INCOME	\$ (71)	\$ (59)	\$ (146)	\$ (121)
INTEREST EXPENSE	174	188	338	376
EXCHANGE LOSSES ⁽¹⁾	716	20	810	53
EQUITY INCOME FROM AFFILIATES ⁽²⁾	(2)	(92)	(147)	(217)
Other, net ⁽³⁾	(78)	(707)	(62)	(904)
TOTAL	\$ 739	\$ (650)	\$ 793	\$ (813)

⁽¹⁾ Includes foreign exchange losses of \$715 million in the second quarter and first six months of 2015 recorded in connection with the revaluation of the company's net monetary assets in Venezuela.

⁽²⁾ Includes the performance of the company's joint ventures and other equity method affiliates, including the Sanofi Pasteur MSD partnership, certain investment funds, as well as AstraZeneca LP until the termination of that relationship on June 30, 2014. Equity income from AstraZeneca LP was \$94 million and \$192 million in the second quarter and first six months of 2014, respectively.

⁽³⁾ Other, net in the second quarter and first six months of 2014 includes a \$741 million gain on AstraZeneca's option exercise.